Cumulatively, our work highlights the mechanism and therapeutic potential of inhibiting IL1β signaling for suppressing or delaying CH-associated expansion, which may apply to the more complex multifactorial CHIP-associated premalignant myeloid expansion observed within patients. The gene discussed is IL1B; the disease is cyclic hematopoiesis.